Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Marco Solmi1 Neuroscience Department, University of Padua;2 Institute for Clinical Research and Education in Medicine, Padua, Italy

Andrea Murru3 Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain

Isabella Pacchiarotti3 Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain

Juan Undurraga4 Department of Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo;5 Early Intervention Program, J. Horwitz Psychiatric Institute, Santiago, Chile

Nicola Veronese2 Institute for Clinical Research and Education in Medicine, Padua, Italy;6 National Research Council, Ageing Section, Padua

Michele Fornaro7 Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, School of Medicine, University “Federico II”, Naples, Italy;8 New York State Psychiatric Institute, Columbia University, New York, NY, USA

Brendon Stubbs2 Institute for Clinical Research and Education in Medicine, Padua, Italy;9 Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London;10 Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London;11 Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK

Francesco Monaco2 Institute for Clinical Research and Education in Medicine, Padua, Italy

Eduard Vieta3 Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain

Mary V Seeman12 Institute of Medical Science, Toronto, ON, Canada

Christoph U Correll13 Department of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks;14 Department of Psychiatry and Molecular Medicine Hempstead, Hofstra Northwell School of Medicine, Hempstead, NY, USA

André F Carvalho2 Institute for Clinical Research and Education in Medicine, Padua, Italy;15 Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, BrazilCorrespondence[email protected]

show all

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Table 1 Main treatment-emergent adverse events related to the use of antipsychotics

Table 2 Neuroreceptor binding profiles of antipsychotics

Table 3 Adverse effect profiles of selected FGA and SGA drugs^#

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Figures & data

Table 1 Main treatment-emergent adverse events related to the use of antipsychotics

Table 2 Neuroreceptor binding profiles of antipsychotics

Table 3 Adverse effect profiles of selected FGA and SGA drugs#

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 3 Adverse effect profiles of selected FGA and SGA drugs^#